New hope for GVHD patients: experimental drug Q702 enters human testing
Disease control
Recruiting now
This early-stage trial tests an experimental drug called Q702 in 18 adults with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug mov…
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC